Alogliptin prevents diastolic dysfunction and preserves left ventricular mitochondrial function in diabetic rabbits

BackgroundThere are increasing evidence that left ventricle diastolic dysfunction is the initial functional alteration in the diabetic myocardium. In this study, we hypothesized that alogliptin prevents diastolic dysfunction and preserves left ventricular mitochondrial function and structure in diabetic rabbits.MethodsA total of 30 rabbits were randomized into control group (CON, n=10), alloxan-induced diabetic group (DM, n=10) and alogliptin-treated (12.5mg/kd/day for 12weeks) diabetic group (DM-A, n=10). Echocardiographic and hemodynamic studies were performed in vivo. Mitochondrial morphology, respiratory function, membrane potential and reactive oxygen species (ROS) generation rate of left ventricular tissue were assessed. The serum concentrations of glucagon-like peptide-1, insulin, inflammatory and oxidative stress markers were measured. Protein expression of TGF-1, NF-B p65 and mitochondrial biogenesis related proteins were determined by Western blotting.ResultsDM rabbits exhibited left ventricular hypertrophy, left atrial dilation, increased E/e ratio and normal left ventricular ejection fraction. Elevated left ventricular end diastolic pressure combined with decreased maximal decreasing rate of left intraventricular pressure (-dp/dtmax) were observed. Alogliptin alleviated ventricular hypertrophy, interstitial fibrosis and diastolic dysfunction in diabetic rabbits. These changes were associated with decreased mitochondrial ROS production rate, prevented mitochondrial membrane depolarization and improved mitochondrial swelling. It also improved mitochondrial biogenesis by PGC-1/NRF1/Tfam signaling pathway.ConclusionsThe DPP-4 inhibitor alogliptin prevents cardiac diastolic dysfunction by inhibiting ventricular remodeling, explicable by improved mitochondrial function and increased mitochondrial biogenesis.